Protein News and Research

RSS

Proteins are complex molecules that are made up of amino acids. They can be found in every cell in the body, and carry out vital processes that keep human beings alive. Mutations in proteins can lead to a multitude of diseases, the most common being cancer.

Disorder in degradation of proteins and other macromolecules in cells leads to serious diseases

The degradation of proteins and other macromolecules in cells is vital to survival. Disruption of this process can result in serious disease. The research group of Professor Thomas Jentsch (Leibniz Institute for Molecular Pharmacology, FMP/ Max Delbr-ck Center for Molecular Medicine, MDC, Berlin-Buch) has now succeeded in identifying an essential cellular process necessary for the transport and degradation of macromolecules in endosomes and lysosomes, respectively.

16 Jun 2010

Sapient Discovery, Helicon Therapeutics enter structural biology collaboration

Sapient Discovery, LLC., a structure-guided drug discovery company, announced today that it has entered into a research collaboration agreement with the Helicon Therapeutics, Inc., a San Diego based pharmaceutical company. Under the terms of the agreement, Sapient Discovery will apply its proprietary structural biology platform and expertise to determine the three-dimensional structures for targets of interest to Helicon Therapeutics, Inc.

16 Jun 2010

NIH awards Geisinger $1.8M grant for study of nuclear ErbB3 protein

A new five-year, $1.8 million National Institutes of Health grant awarded to staff scientist Nikolaos Tapinos, M.D., Ph.D., of Geisinger's Sigfried and Janet Weis Center for Research will be used to study the role of nuclear ErbB3 protein during development of the nervous system and in response to nerve injury.

16 Jun 2010

AMRI announces acquisition of Hyaluron

AMRI today announced the acquisition of Hyaluron Inc., expanding AMRI's contract manufacturing capabilities to include cGMP manufacturing and sterile filling of parenteral drugs to the biopharmaceutical industry. AMRI has acquired all facilities and equipment as well as a highly trained and experienced staff of professionals with expertise in sterile GMP manufacturing. Purchase price, including debt, was approximately $27 million.

15 Jun 2010

Alexion's Soliris may benefit patients with thrombotic microangiopathy from uncontrolled complement activation

Researchers reported today that Soliris® (eculizumab), a first-in-class terminal complement inhibitor developed by Alexion Pharmaceuticals, Inc., may provide clinical benefits to patients with thrombotic microangiopathy (TMA) resulting from uncontrolled complement activation. TMA, the formation of blood clots in capillaries and small arteries, can lead to life-threatening damage in multiple organs including kidney failure, thrombocytopenia (abnormally low platelet count) and anemia.

15 Jun 2010

Inovio commences immunization in U.S. Phase I clinical trial of SynCon H5N1 influenza DNA vaccine

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it has immunized its first subject in a U.S. Phase I clinical trial to evaluate its SynCon™ H5N1 (avian) influenza DNA vaccine, VGX-3400X.

15 Jun 2010

Help Conquer Cancer Project taps World Community Grid to discover structure of cancer-related proteins

Scientists have devised a way to automate and accelerate a manual, complex process that enables researchers to more easily discover the structure of cancer-related proteins, and, eventually, formulate cancer cures. This new, automated approach may also help the exploration of other diseases and food-related research.

15 Jun 2010

New insight into transmission of prion diseases

Prion diseases are lethal neurodegenerative disorders that include Creutzfeldt-Jakob disease (CJD) in humans and bovine spongiform encephalopathy (BSE; commonly known as mad cow disease) in cows. A team of researchers, led by Adriano Aguzzi and Christina Sigurdson, at Universit-tsSpital Z-rich, Switzerland, has generated data in mice that provides greater understanding of the factors that determine how easy it is for prion diseases to be transmitted to a new host species.

15 Jun 2010

Depression and other stress-related psychiatric disorders in women may have biological basis: Research

There may be a biological reason why depression and other stress-related psychiatric disorders are more common among women compared to men. Studying stress signaling systems in animal brains, neuroscience researchers found that females are more sensitive to low levels of an important stress hormone and less able to adapt to high levels than males.

15 Jun 2010

Sulindac shuts down cancer cell growth, initiates cell death: Study

Without knowing exactly why, scientists have long observed that people who regularly take non-steroidal anti-inflammatory drugs like aspirin have lower incidences of certain types of cancer. Now, in a study appearing in Cancer Cell on June 15, investigators at Sanford-Burnham Medical Research Institute and their colleagues have figured out how one NSAID, called Sulindac, inhibits tumor growth.

15 Jun 2010

Trubion announces Pfizer's decision to discontinue development of TRU-015 for RA

Trubion Pharmaceuticals, Inc. today announced Pfizer's decision to discontinue development of TRU-015 (PF-05212374), an investigational drug in Phase 2 evaluation for the treatment of rheumatoid arthritis (RA) developed under the companies' CD20 collaboration. However, Pfizer has confirmed that it will continue to develop SBI-087 (PF-05230895), Trubion's next-generation, humanized, subcutaneous CD20 RA product candidate also in Phase 2 clinical evaluation.

15 Jun 2010

CLC-5 protein plays active part in inherited kidney disorder: Scientists

Scientists from the University of Leeds have discovered the mechanisms of a protein known to play an active part in the inherited kidney disorder, Dent's disease. The findings provide a new focus for future therapies for the disease, for which there is currently no cure.

15 Jun 2010

MP Biomedicals to acquire ICPbio International

MP Biomedicals LLC announced today that it has signed a definitive agreement to acquire the assets of ICPbio International LTD., an Auckland, New Zealand based protein biologics manufacturing company, subject to normal closing adjustments. This acquisition places MP Biomedicals in a strong position to pursue sales and distribution of serum protein products used in research and manufacturing in the Biopharmaceutical, In vitro diagnostic and Biotech sectors.

From MP Biomedicals, LLC 14 Jun 2010

BioScale secures $25 million for commercialization of ViBE protein analytics systems

BioScale Inc., a privately-held life science company that develops, manufactures and promotes a new generation of protein analytics technology, today announced that it has secured $25 million in its recent financing round. Led by new investor Morningside Venture, this round will be used to expand manufacturing operations and commercial sales of the ViBE protein analytics systems. Also participating in the financing were existing investors New Science Ventures, WFD Ventures, F2 Ventures, and several individual investors

14 Jun 2010

Faron, Priaxon enter collaboration to develop new AOC3/SSAO antagonists

Faron Pharmaceuticals Ltd., Turku, Finland and Priaxon AG, Munich, Germany today announced the entry into a collaboration and commercialization agreement to obtain new superior AOC3/SSAO antagonists. This collaboration combines two world-class technologies, the thorough understanding of the AOC3-protein and its ligand interaction with the rapid discovery engine for the development of new chemical inhibitors of protein-protein interactions.

14 Jun 2010

TF12 antibody targets EGP-1 expressed in epithelial cancer: Immunomedics

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that TF12, in combination with radiolabeled peptides, produced specific, fast, high-contrast imaging and pretargeted radioimmunotherapy of epithelial cancers that include cancers of the prostate and the ovary.

14 Jun 2010

Olfactory function tests could help in treating patient in early stages of PD

A fast, simple and non invasive test of the ability to smell may be an important tool to screen people who are likely to develop Parkinson's disease, in which motor symptoms only become evident at a later stage of the disease, a German scientist will tell the annual conference of the European Society of Human Genetics today (Saturday).

14 Jun 2010

New guideline to improve IHC testing for expression status of ER and PgR in breast cancer issued

The College of American Pathologists and the American Society of Clinical Oncology today issued a joint guideline aimed at improving the accuracy of immunohistochemistry testing for the expression status of estrogen and progesterone receptors in breast cancer. The two groups conducted a systematic review of medical research literature in partnership with Cancer Care Ontario to develop the recommendations.

14 Jun 2010

Researchers transform yellow fever vaccine to fend off mosquito borne parasites that cause malaria

There is no vaccine for malaria, which sickens almost a quarter of a billion people each year and kills a child every 30 seconds. That could be changing: researchers at The Rockefeller University have genetically transformed the yellow fever vaccine to prime the immune system to fend off the mosquito borne parasites that cause the disease.

14 Jun 2010

Study may yield more targeted therapies for telomere associated diseases

A new study at the University of Leicester is examining a sequence of DNA- known as telomeres - that varies in length between individual.

14 Jun 2010

Protein News and Research

Further Reading

Disorder in degradation of proteins and other macromolecules in cells leads to serious diseases

Sapient Discovery, Helicon Therapeutics enter structural biology collaboration

NIH awards Geisinger $1.8M grant for study of nuclear ErbB3 protein

AMRI announces acquisition of Hyaluron

Alexion's Soliris may benefit patients with thrombotic microangiopathy from uncontrolled complement activation

Inovio commences immunization in U.S. Phase I clinical trial of SynCon H5N1 influenza DNA vaccine

Help Conquer Cancer Project taps World Community Grid to discover structure of cancer-related proteins

New insight into transmission of prion diseases

Depression and other stress-related psychiatric disorders in women may have biological basis: Research

Sulindac shuts down cancer cell growth, initiates cell death: Study

Trubion announces Pfizer's decision to discontinue development of TRU-015 for RA

CLC-5 protein plays active part in inherited kidney disorder: Scientists

MP Biomedicals to acquire ICPbio International

BioScale secures $25 million for commercialization of ViBE protein analytics systems

Faron, Priaxon enter collaboration to develop new AOC3/SSAO antagonists

TF12 antibody targets EGP-1 expressed in epithelial cancer: Immunomedics

Olfactory function tests could help in treating patient in early stages of PD

New guideline to improve IHC testing for expression status of ER and PgR in breast cancer issued

Researchers transform yellow fever vaccine to fend off mosquito borne parasites that cause malaria

Study may yield more targeted therapies for telomere associated diseases

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News